(WBA) Walgreens Boots Alliance - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US9314271084
WBA: Pharmacy, Healthcare, Beauty, Wellness, Medicines, Services
Walgreens Boots Alliance (WBA) is a global leader in healthcare, pharmacy, and retail, operating across the U.S., Germany, the U.K., and other international markets. The company is structured into three core segments: U.S. Retail Pharmacy, International, and U.S. Healthcare. Each segment plays a critical role in WBAs diversified business model, which spans traditional retail pharmacy services, health and wellness offerings, and value-based care solutions.
The U.S. Retail Pharmacy segment is the backbone of WBAs domestic operations, encompassing over 13,000 retail drugstores across the U.S. These locations provide a wide range of services, including health and wellness programs, specialty pharmacy services, and home delivery options. The segment also generates significant revenue from the sale of beauty, personal care, and general merchandise products, making it a key contributor to WBAs overall profitability.
Internationally, WBA operates a robust network of pharmacy-led health and beauty retail businesses under the Boots brand in the U.K., Ireland, and Thailand. Additionally, the company has a strong presence in Latin America through its Benavides and Ahumada brands in Mexico and Chile, respectively. This segment focuses on prescription drugs, health and wellness products, and consumer goods, catering to diverse markets with varying regulatory and consumer demands.
The U.S. Healthcare segment represents WBAs strategic push into value-based care and integrated healthcare services. This includes VillageMD, a rapidly growing provider of primary, specialty, and urgent care services delivered through traditional clinics, in-home visits, and telehealth platforms. Shields, a specialty pharmacy integrator, and CareCentrix, a leader in post-acute and home care management, further strengthen WBAs position in the healthcare ecosystem. These investments highlight WBAs commitment to transitioning from a traditional retail pharmacy model to a more comprehensive healthcare provider.
From a financial perspective, WBAs market cap of $9.9 billion reflects its scale and stability. The forward P/E of 7.69 indicates investor confidence in the companys ability to deliver growth, particularly as it expands its healthcare offerings. However, the current P/E of 0.00 suggests that WBA
Additional Sources for WBA Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
WBA Stock Overview
Market Cap in USD | 9,290m |
Sector | Healthcare |
Industry | Pharmaceutical Retailers |
GiC Sub-Industry | Drug Retail |
IPO / Inception | 1985-07-01 |
WBA Stock Ratings
Growth 5y | -80.0% |
Fundamental | -35.2% |
Dividend | 40.1% |
Rel. Strength Industry | -46.2 |
Analysts | 3/5 |
Fair Price Momentum | 9.29 USD |
Fair Price DCF | - |
WBA Dividends
Dividend Yield 12m | 6.90% |
Yield on Cost 5y | 2.17% |
Annual Growth 5y | -11.60% |
Payout Consistency | 96.5% |
WBA Growth Ratios
Growth Correlation 3m | 40% |
Growth Correlation 12m | -58.6% |
Growth Correlation 5y | -76.9% |
CAGR 5y | -20.09% |
CAGR/Max DD 5y | -0.24 |
Sharpe Ratio 12m | -1.39 |
Alpha | -46.63 |
Beta | 0.11 |
Volatility | 74.97% |
Current Volume | 10039.6k |
Average Volume 20d | 22558.8k |
As of March 15, 2025, the stock is trading at USD 11.23 with a total of 10,039,613 shares traded.
Over the past week, the price has changed by -1.40%, over one month by +15.77%, over three months by +10.31% and over the past year by -41.74%.
Probably not. Based on ValueRay Fundamental Analyses, Walgreens Boots Alliance (NASDAQ:WBA) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -35.16 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of WBA as of March 2025 is 9.29. This means that WBA is currently overvalued and has a potential downside of -17.28%.
Walgreens Boots Alliance has received a consensus analysts rating of 3.00. Therefor, it is recommend to hold WBA.
- Strong Buy: 2
- Buy: 1
- Hold: 12
- Sell: 1
- Strong Sell: 2
According to ValueRays Forecast Model, WBA Walgreens Boots Alliance will be worth about 10 in March 2026. The stock is currently trading at 11.23. This means that the stock has a potential downside of -10.69%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 11.8 | 4.9% |
Analysts Target Price | 11 | -2.3% |
ValueRay Target Price | 10 | -10.7% |